• Bleeding is a rare symptom, according to the Africa CDC
  • Children are disproportionately affected by the outbreak

More than six months into a devastating Ebola outbreak in the Democratic Republic of Congo, scientists and medics are beginning to gain a better understanding of the rare Bundibugyo strain of the virus. Their findings could help explain its rapid spread and, ultimately, help bring it under control.

With over 11,000 cases and more than 5,500 deaths recorded so far, the Bundibugyo virus is spreading at double the pace of the 2014–2016 Ebola outbreak in West Africa, which remains the largest on record. Currently, there are no licensed treatments or vaccines specifically approved to fight this strain.

The outbreak’s location in a region of eastern Congo already grappling with a severe humanitarian crisis has complicated scientific investigations, several experts warned. They cautioned against drawing premature conclusions, noting that data is often limited, highly variable, and difficult to collect under the circumstances.

“There are so many different factors to compare across outbreaks, even within outbreaks — it is really hard,” said Daniel Bausch, a member of the World Health Organization’s (WHO) Ebola emergency committee and a visiting professor at the Geneva Graduate Institute in Switzerland.

Catherine Smallwood, the WHO’s Ebola incident manager, stated that teams are actively gathering evidence to better inform the response efforts. “Soon we’ll be able to make some bold statements about what’s the same, what’s different, and what we need to adjust,” she said.

Bleeding Less Common

A key area of investigation focuses on the symptoms of Bundibugyo, particularly in children, according to the WHO and the Africa Centers for Disease Control and Prevention (Africa CDC).

While typical Ebola infections can cause fever, vomiting, diarrhea, and in severe cases, internal and external bleeding, hemorrhagic symptoms appear to be less common with the Bundibugyo strain. Yap Boum, the Africa CDC’s deputy Ebola incident manager, noted that bleeding occurs in only around 5% to 10% of confirmed cases in the current outbreak. This is significantly lower than in outbreaks of the more prevalent Zaire strain of Ebola.

This atypical presentation makes the disease easier to confuse with other common illnesses like malaria. Boum explained that this similarity could have contributed to the late detection of the outbreak, compounded by early diagnostic challenges, as standard tests designed for other Ebola species do not detect Bundibugyo.

The lack of obvious bleeding symptoms also makes tracking the spread more difficult, as many people do not suspect Ebola and seek care elsewhere. Currently, around 70% of patients are dying in their communities rather than in healthcare centers.

Although the outbreak was officially declared in May, the WHO and Africa CDC believe transmission may have been occurring for months prior to that announcement.

Jean-Jacques Muyembe, co-discoverer of Ebola and head of Congo’s National Institute for Biomedical Research, added that bleeding also seems to occur later in the disease course for some patients. Bausch noted that many scientists now believe bleeding is less of a hallmark symptom for all Ebola viruses than previously thought, though it appears even rarer for Bundibugyo patients.

Risk to Children

The situation is particularly complex for young children, according to the WHO’s Smallwood. Gastrointestinal symptoms are more common than fever in this age group, which complicates early diagnosis and treatment. This may be a key reason why children are being disproportionately affected by the outbreak.

According to the latest data from the Congolese Ministry of Health and the WHO, there have been 1,207 confirmed Ebola cases in children under the age of 5, with 844 of them resulting in death—a fatality rate of roughly 7 in 10. This is higher than the rate among adults, which stands at around 50%. While this adult fatality rate is above previous Bundibugyo outbreaks, it remains below the typical rates for the Zaire strain, which can reach up to 80% without treatment.

Remaining Questions

Despite the progress made, many critical questions remain, according to leading experts. Key areas of ongoing study include the prevalence of mild symptoms and the long-term health implications for survivors. Approximately 700 survivors have enrolled in follow-up studies and support programs, the WHO said.

Genomic sequencing has shown that, unlike some other pathogens, the Bundibugyo virus is not changing rapidly or becoming more transmissible. However, research remains a significant challenge when so many cases go undetected before victims die in their communities.

“If we don’t find the ones that are severely sick, what is our hope of finding the ones that are only mildly sick?” asked Sylvie Jonckheere, Médecins Sans Frontières’ adviser on emerging and reemerging infectious diseases.

Experts emphasized that prompt access to quality care significantly improves survival rates. They also noted that progress in containing the outbreak in early hotspots demonstrates that standard control measures, such as patient isolation, are effective. Like the Zaire strain, Bundibugyo appears to transmit only when patients are symptomatic.

However, the primary research question remains: which vaccines and treatments will be effective against this specific strain. A trial of Merck’s Ervebo vaccine, which was developed to prevent the Zaire strain, is currently assessing whether it might offer cross-protection for Bundibugyo.

New vaccines developed specifically for the Bundibugyo strain are expected to enter clinical trials soon. Additionally, healthcare workers in Congo are testing prophylactic antivirals and treatments from Gilead Sciences and Mapp Biopharmaceuticals.

“When we started, we said there are no vaccines, no treatments,” Boum noted. “If we start proving we have some efficacy… it becomes a game changer.”

Source link

Exit mobile version